NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Galecto Provides Enrollment Update on Phase 2a MYLOX-1 Trial and Reiterates Expected Timing of Multiple Data Readouts in 2022<
20 Dec 2021

Galecto Provides Enrollment Update on Phase 2a MYLOX-1 Trial and Reiterates Expected Timing of Multiple Data Readouts in 2022

Anticipates interim data in mid-2022 and topline data from full trial in 2H 2022.
Lava Therapeutics to present corporate overview at 40TH annual J.P. Morgan healthcare conference<
20 Dec 2021

Lava Therapeutics to present corporate overview at 40TH annual J.P. Morgan healthcare conference

Stephen Hurlywill present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 12
NorthSea Therapeutics Completes US$80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders<
17 Dec 2021

NorthSea Therapeutics Completes US$80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders

The financing round was co-led by Ysios Capital and Forbion Growth and joined by new investors; a large managed care organization, and Hercules Capital, Inc.
First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Reversal Agent, VMX-C001<
15 Dec 2021

First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Reversal Agent, VMX-C001

Major corporate milestone achieved as VarmX transitions into a clinical-stage company
Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial<
13 Dec 2021

Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial

GB1211 observed to be safe and well tolerated in initial twelve randomized subjects, including six hepatically impaired liver cirrhosis patients
SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer<
10 Dec 2021

SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer

Raffaella Toso, PhD, joins as VP Corporate Development & Alliance Management and Florence Paliargues appointed as VP Portfolio Project Management.
ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors<
02 Dec 2021

ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors

Seasoned biotech executive with a wealth of experience and a track-record of strategic alliances in the immuno-oncology space.
Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders<
01 Dec 2021

Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders

Carmel M. Lynch, PhD, as Chief Development Officer (CDO) and Pernille Høyrup Hemmingsen, PhD, as Chief Technology Officer (CTO). Dennis Benjamin, PhD, will support the Company as Research Fellow & Chairman of the Scientific Advisory Board (SAB).
Dutch med-tech innovator Xeltis lands €15 million European financing from EIB<
22 Nov 2021

Dutch med-tech innovator Xeltis lands €15 million European financing from EIB

Xeltis will use the funding to accelerate the clinical programmes of three restorative devices that can substantially impact cardiovascular
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology<
22 Nov 2021

Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology

Purchase price includes an upfront payment of EUR 205 million, precommercial milestones for up to EUR 170 million and progressive commercial milestones.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.